Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802

Blood

Volumn 124, Issue 22, 2014, Pages 3221-3227

  Bolaños Meade, Javier ^a,b   Logan, Brent R ^c   Alousi, Amin M ^d   Antin, Joseph H ^e   Barowski, Kate ^f   Carter, Shelly L ^f   Goldstein, Steven C ^g   Hexner, Elizabeth O ^h   Horowitz, Mary M ^c   Lee, Stephanie J ^i,j   Levine, John E ^g   MacMillan, Margaret L ^k   Martin, Paul J ^i,j   Mendizabal, Adam M ^f   Nakamura, Ryotaro ^l   Pasquini, Marcelo C ^c   Weisdorf, Daniel J ^k   Westervelt, Peter ^m   Ho, Vincent T ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f EMMES CORPORATION   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

^l CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^m WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CEREBELLAR ATAXIA; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT SURVIVAL; HOSPITAL READMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FISTULA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORGAN DISTRIBUTION; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEPTIC SHOCK; SURVIVAL; SYSTEMIC THERAPY; VIRUS REACTIVATION; ACUTE DISEASE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; GRAFT REJECTION; GRAFT VS HOST DISEASE; MIDDLE AGED; PATHOLOGY; PROCEDURES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PLACEBOS; PREDNISONE; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84911435257     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-577023     Document Type: Article

References (15)

1. Anasetti C, Logan BR, Lee SJ, et al; Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-1496.
2. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75(4):1024-1030.
3. Alousi AM, Weisdorf DJ, Logan BR, et al; Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus- host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114(3):511-517.
4. Lee SJ, Zahrieh D, Agura E, et al. Effect of upfront daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004;104(5):1559-1564.
5. Roy J, McGlave PB, Filipovich AH, et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant. 1992;10(1):77-82.
6. Cahn JY, Bordigoni P, Tiberghien P, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation. 1995;60(9):939-942.
7. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 1996;88(3):824-830.
8. Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6(4A):441-447.
9. Couriel DR, Saliba R, de Lima M, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15(12):1555-1562.
10. Jacobson PA, Huang J, Wu J, et al. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2010;16(3):421-429.
11. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
12. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634-1646.
13. Luft T, Dietrich S, Falk C, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood. 2011;118(6):1685-1692.
14. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012;119(16):3854-3860.
15. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529-539.